Clinical trials: Inflammatory Bowel Disease 1
Irritable Bowel Syndrome-like Symptoms, Crohn Disease Remission
A Prospective Trial in Patients With Crohn's Disease in Remission and Having Irritable Bowel Syndrome-like Symptoms
Crohn's disease is a chronic and complex inflammatory bowel disease affecting the gastrointestinal tract, causing symptoms like abdominal pain, diarrhea, and fatigue.
- Trial name
- Relieve (NCT06104631)
- Testing
- BK003
- Where
- 2 sites in Belgium, France
- Volunteers
- 50 people
- Sponsor
- Biokuris s.a.
Inflammatory Bowel Disease, Crohn Disease
Deep Endoscopic Remission Assessed by a Surrogate Biomarker in Patients With Inflammatory Bowel Disease
We hypothesize that the number of needed endoscopic procedure performed at IBD patients (adult and children), can be reduced by using an individualized algorithm of symptoms, blood and faecal biomarkers.
- Conditions
- Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis
- Trial name
- NCT01861288
- Where
- Denmark
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Herlev Hospital
Crohn Disease, Microbial Substitution
Fecal Microbial Transplantation and Vedolizumab Treatment of Crohn's Disease
The investigators postulate that by determining a patient's baseline microbiome and manipulating it through fecal microbial transplantation (FMT) may improve response rates to vedolizumab in Crohn's disease (CD) patients.
- Trial name
- NCT04328922
- Testing
- Fecal microbial transplantation
- Where
- 2 sites in Israel
- Volunteers
- 80 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Colitis, Ulcerative
A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants
"GSK4528287 is a drug being developed to treat like inflammatory bowel diseases like Crohns disease and ulcerative colitis. This study is the first time that GSK4528287 will be given to humans.
- Trial name
- NCT06681181
- Testing
- GSK4528287
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Moderately to Severely Active Crohns Disease
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's…
- Trial name
- SIBERITE-2 (NCT06819891)
- Testing
- Afimkibart
- Where
- 208 sites in United States, Argentina and 25 more
- Volunteers
- 425 people
- Sponsor
- Hoffmann-La Roche
Crohn Disease, Ulcerative Colitis
Autoimmune Protocol Diet and Inflammatory Bowel Disease
There is limited data to guide the use of dietary change in the management of IBD, and it can prove challenging to implement in the setting of altered anatomy, comorbid conditions, and patient compliance.
- Conditions
- Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
- Trial name
- NCT03512327
- Testing
- Autoimmune protocol (AIP) diet
- Volunteers
- 15 people
- Sponsor
- Scripps Health
Crohn's Disease
Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis
This study proposes a randomized prospective study comparing the Kono-S anastomosis to the standard side-to-side anastomosis.This will be a multi-center randomized prospective trial.
- Trial name
- NCT03256240
- Testing
- side-to-side functional end anastomosis, Kono-S analstomosis
- Where
- 15 sites in United States, Belgium and 4 more
- Volunteers
- 600 people
- Sponsor
- Weill Medical College of Cornell University
Crohn's Disease
A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)
A 26 week study to examine the efficacy, safety and pharmacokinetics of CDP870 in Crohn's disease
- Trial name
- NCT00152490
- Testing
- Certolizumab Pegol (CDP870)
- Volunteers
- 604 people
- Sponsor
- UCB Pharma
Crohn Disease
Can Intermittent Fasting Induce Weight Loss and Improve Gut Health as Compared to Standard Medical Care in Patients With Obesity/High BMI and Crohn's Disease.
Diet is a determinant of gut microbial diversity and composition and is recognized as a potential environmental trigger for IBD; for example, high-fat diets are associated with increased risk of CD in pre-clinical models, with…
- Trial name
- CD-Fast (NCT05230160)
- Testing
- Intermittent Fasting
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- University of Calgary
Crohns Disease
Treatment of Moderate to Severe Refractory Crohn's Disease
This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD).
- Trial name
- NCT06721962
- Testing
- TRX103, Cyclophosphamide
- Where
- 13 sites in United States
- Volunteers
- 39 people
- Sponsor
- Tr1X, Inc.
Crohn's Disease
Extension Study of MT-1303 in Subjects With Crohn's Disease
The primary objectives of the study are: -To evaluate the long-term safety and tolerability of MT-1303 in subjects with moderate to severe active Crohn's Disease（CD）
- Trial name
- NCT02389790
- Testing
- MT-1303
- Where
- 11 sites in Czechia, France and 9 more
- Volunteers
- 46 people
- Sponsor
- Tanabe Pharma Corporation
Crohn Disease, Blood Clot
Thrombin Generation in Crohn's Disease
One hundred and fifty patients with Crohn's disease involving the terminal ileum or the colon, in clinical remission, with or without endoscopic activity will be included.
- Conditions
- Crohn Disease, Blood Clot, Thrombosis
- Trial name
- NCT02445690
- Where
- 3 sites in Brazil
- Volunteers
- 150 people
- Sponsor
- University of Sao Paulo General Hospital
Crohn's Disease
Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)
This 26-week extension study evaluates the efficacy and safety of certolizumab pegol administered subcutaneously every 4 weeks (dosed at Weeks 16, 20, 24, 28 and 32) in subjects with active Crohn's disease who had no clinical…
- Trial name
- NCT00329420
- Testing
- Certolizumab pegol
- Where
- 23 sites in Japan
- Volunteers
- 46 people
- Sponsor
- UCB Pharma
Crohn Disease, Vitamin D Deficiency
Effects of Supplementation of Vitamin D in Patients With Crohn's Disease
Thus, the aim of the current study is to assess the influence of vitamin D deficiency and, consequently, of serum calcium deficiency in the body composition, muscular activity, bone mineral density, fatigue, and exercise…
- Conditions
- Crohn Disease, Vitamin D Deficiency, Fatigue, Sarcopenia
- Trial name
- NCT02704624
- Testing
- Vitamin D
- Where
- Brazil
- Volunteers
- 110 people
- Sponsor
- Federal University of Juiz de Fora
Crohn's Disease
Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease
180 patients suffering from active Crohn's disease with evidence of mucosal ulceration will be evaluated for improvement of disease activity (efficacy) when taking GLPG0634 or matching placebo once daily for 20 weeks in addition…
- Trial name
- NCT02048618
- Testing
- GLPG0634
- Where
- 63 sites in Belgium, Czechia and 7 more
- Volunteers
- 175 people
- Sponsor
- Lakefront Biotherapeutics NV
Fibrostenotic Crohn's Disease
A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease
This is a Phase 1b, open-label, exploratory study designed to evaluate the pharmacodynamic effects of PALI-2108, a phosphodiesterase-4 (PDE4) inhibitor, in patients with fibrostenotic Crohn's disease (FSCD).
- Trial name
- NCT07428096
- Testing
- PALI-2108
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Palisade Bio
Crohn Disease
Validation of an IUS Activity Index
The primary objective of this study is to prospectively validate a novel intestinal ultrasound (IUS) Crohn's disease (CD) activity index and component items, correlating CD activity and responsiveness to therapy as evaluated by…
- Trial name
- USE-IT (NCT05407350)
- Testing
- Ultrasound, Colonoscopy, MRE
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- International Bowel Ultrasound Group e.V.
Inflammatory Bowel Disease, Crohn's Disease
Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease
Drug serum concentrations will be measured at several time-points for inflammatory disease patients treated with anti-TNF agents.
- Conditions
- Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
- Trial name
- NCT02073526
- Testing
- Infliximab, adalimumab, certolizumab pegol
- Where
- Norway
- Volunteers
- 1,230 people
- Sponsor
- Oslo University Hospital
Fibrostenotic Crohn's Disease
Human Mass Balance Study of [14C] Ontunisertib in Healthy Volunteers
This is an open, two-part study in healthy male volunteers, aged 30-65 years. This trial aims to understand how the human body absorbs, distributes, metabolizes and eliminates ontunisertib after a single oral dose of…
- Trial name
- NCT07672574
- Testing
- Ontunisertib, [14C]ontunisertib
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Agomab Spain S.L.U.
Crohn's Disease
Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease
This is a multi-centre, randomized, double-blind, dose response clinical study of CDP870 in patients with Crohn's disease.
- Trial name
- NCT00291668
- Testing
- Certolizumab Pegol
- Where
- 22 sites in Japan
- Volunteers
- 94 people
- Sponsor
- UCB Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.